TNON earnings analysis
What we found in TNON's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Tenon delivered strong year-over-year growth, with revenue rising 127% to $1.279 million and gross margin expanding to 64.0%, but the quarter materially missed consensus and remained deeply unprofitable. The $4.050 million net loss, $4.168 million of operating expenses, $5.2 million September 2026 note maturity, and ineffective disclosure controls create substantial financial and execution risk. The $4.2 million July offering improves near-term liquidity, but no quantitative financial guidance was provided.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue growth continued
- Second-quarter revenue was $1.279 million, up 127% year over year and approximately 27.9% from $1.000 million in 2026 Q1.
- Gross margin expanded year over year
- Gross margin was 64.0%, improving from 43.4% in the prior-year quarter, a 20.6-percentage-point increase, although it declined from 68.5% in 2026 Q1.
- July financing added liquidity
- The company completed a public offering that generated approximately $4.2 million in gross proceeds in July 2026, providing additional near-term liquidity.
- Training supported procedure growth
- Management reported record July procedure activity following physician training initiatives, supporting the sequential revenue increase from $1.000 million to $1.279 million.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Revenue and EPS missed estimates
- Revenue of $1.279 million was $0.261 million below the $1.540 million consensus estimate, while EPS of negative $12.35 missed the negative $8.40 estimate by $3.95 per share.
- Large operating losses persist
- The company reported a $4.050 million net loss and $4.168 million of operating expenses for the quarter, indicating that operating costs continue to substantially exceed the $1.279 million revenue base.
- Near-term debt maturity pressure
- The $5.2 million convertible notes mature in September 2026, shortly after the $4.2 million July public offering, creating a significant near-term refinancing or repayment requirement.
- Material weakness in controls
- As of June 30, 2026, management concluded that disclosure controls and procedures were not effective and identified inadequate segregation of accounting duties as a material weakness.
- No formal risk-factor updates
- The company disclosed 0 material changes to its previously reported risk factors compared with the Form 10-K filed on March 27, 2026; the principal new filing-level concern is the ineffective-controls conclusion as of June 30, 2026.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-12.35
- Gross margin
- 64.0%
What they said about what is next.
No quantitative revenue or EPS guidance was provided in the 10-Q. The filing does not establish a prior company outlook against which to assess a raise, maintenance, or reduction.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 15, 2026
- Tenon Medical, Inc. reported Q1 2026 revenue of $1.38 million, a 90% increase from $726,000 in Q1 2025, driven by higher surgical procedures and the SImmetry+ System addition. However, the company experienced a net loss…
- 10-K · March 27, 2026
- Tenon positions itself as a focused SI‑joint implant company with two commercial platforms (Catamaran® and the August 2025‑acquired SImmetry+®) and a U.S. commercialization focus. The filing discloses recent financings…
- 10-Q · November 13, 2025
- Tenon Medical reported strong Q3 2025 results with record revenue of $1.173 million, a 32% increase from $887,000 in Q3 2024. The gross margin improved significantly to 65.9%, reflecting a continuation of positive…
- 10-Q · August 13, 2025
- Tenon Medical reported Q2 revenue of $564,000, down from $901,000 in Q2 2024, while GAAP net loss narrowed to $(2,769,000) and EPS improved to $(0.36). Management reduced operating expenses (total operating expenses…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing TNON makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever